Fluconazole Treatment Is Effective against a Candida albicans erg3/erg3 Mutant In Vivo Despite In Vitro Resistance
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Candida albicans ERG3 encodes a sterol C5,6-desaturase which is essential for synthesis of ergosterol. Defective sterol C5,6 desaturation has been considered to be one of the azole resistance mechanisms in this species. However, the clinical relevance of this resistance mechanism is still unclear. In this study, we created a C. albicans erg3/erg3 mutant by the “Ura-blaster” method and confirmed the expected azole resistance using standard in vitro testing and the presence of ergosta-7,22-dien-3β-ol instead of ergosterol. For in vivo studies, a wild-type URA3 was placed back into its native locus in the erg3 homozygote to avoid positional effects on URA3 expression. Defective hyphal formation of the erg3 homozygote was observed not only in vitro but in kidney tissues. A marked attenuation of virulence was shown by the longer survival and the lower kidney burdens of mice inoculated with the reconstituted Ura + erg3 homozygote relative to the control. To assess fluconazole efficacy in a murine model of disseminated candidiasis, inoculum sizes of the control and the erg3 homozygote were chosen which provided a similar organ burden. Under these conditions, fluconazole was highly effective in reducing the organ burden in both groups. This study demonstrates that an ERG3 mutation causing inactivation of sterol C5,6-desaturase cannot confer fluconazole resistance in vivo by itself regardless of resistance measured by standard in vitro testing. The finding questions the clinical significance of this resistance mechanism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sanglard, D., Kuchler, K., Ischer, F., Pagani, J. L., Monod, M., & Bille, J. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.11.2378 · Cited by 815 · cited 3×
“MDR1, a gene encoding a membrane transport protein of the major facilitator superfamily (34), was not expressed detectably in any of the strains (data not shown).”
BackgroundPerea, S., López-Ribot, J. L., Kirkpatrick, W. R., McAtee, R. K., Santillán, R. A., Martı́nez, M., Calabrese, D., Sanglard, D., & Patterson, T. F. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2676-2684.2001 · Cited by 470 · cited 1×
“Both mutations in the ERG11 gene and increased drug efflux are quite common (27, 35).”
BackgroundResistance Mechanisms in Clinical Isolates of Candida albicans
White, T. C., Holleman, S., Dy, F., Mirels, L. F., & Stevens, D. A. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1704-1713.2002 · Cited by 461
Sanglard, D., Ischer, F., Parkinson, T., Falconer, D., & Bille, J. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.8.2404-2412.2003 · Cited by 398 · cited 5×
“Alteration of amino acid composition of lanosterol 14 demethylase (37), increased drug efflux (32, 34), and altered ergosterol synthetic pathways due to blockage of sterol C5,6desaturase encoded by ERG3 (17, 33) have been known as factors contributing to azole resistance in C.”
BackgroundResultInfluentialEvolution of antifungal-drug resistance: mechanisms and pathogen fitness
Anderson, J. B. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1179 · Cited by 375
Kelly, S. L., Lamb, D. C., Kelly, D. E., Manning, N. J., Loeffler, J., Hebart, H., Schumacher, U., & Einsele, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(96)01360-9 · Cited by 351 · cited 3×
“However, clinical significance of this resistance mechanism is still controversial, because only a few azole-resistant clinical isolates have exhibited a sterol profile indicative of defective sterol C5,6 desaturation (4, 18 , 26).”
BackgroundInfluentialUpregulation of ERG Genes in Candida Species by Azoles and Other Sterol Biosynthesis Inhibitors
Henry, K. W., Nickels, J. T., & Edlind, T. D. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.10.2693-2700.2000 · Cited by 216 · cited 1×
“with primers described previously (12).”
Geber, A., Hitchcock, C. A., Swartz, J. E., Pullen, F. S., Marsden, K. E., Kwon-Chung, K. J., & Bennett, J. E. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.12.2708 · Cited by 203 · cited 1×
“However, no relation between defective sterol C5,6-desaturase and azole resistance was found in Candida glabrata (9).”
BackgroundSelf-citationLay, J., Henry, L. K., Clifford, J., Koltin, Y., Bulawa, C. E., & Becker, J. M. (1998) · Infection and Immunity · doi:10.1128/iai.66.11.5301-5306.1998 · Cited by 174
Rex, J. H., Nelson, P. W., Paetznick, V. L., Lozano-Chiu, M., Espinel-Ingroff, A., & Anaissie, E. J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.1.129 · Cited by 167 · cited 1×
“albicans isolates have been shown to exhibit significant trailing growth, which is also known as a low-high MIC phenotype (23, 29).”
BackgroundThe Trailing End Point Phenotype in Antifungal Susceptibility Testing Is pH Dependent
Marr, K. A., Rustad, T. R., Rex, J. H., & White, T. C. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.6.1383 · Cited by 145 · cited 1×
“albicans isolates have been shown to exhibit significant trailing growth, which is also known as a low-high MIC phenotype (23, 29).”
BackgroundMiyazaki, Y., Geber, A., Miyazaki, H., Falconer, D., Parkinson, T., Hitchcock, C., Grimberg, B., Nyswaner, K., & Bennett, J. E. (1999) · Gene · doi:10.1016/s0378-1119(99)00263-2 · Cited by 71 · cited 13×
“Northern blot analysis of ERG3, ERG11, and drug efflux pump genes.”
BackgroundInfluentialSelf-citationErgosterol gene expression in wild-type and ergosterol-deficient mutants of Candidaalbicans
Pierson, C. A., Eckstein, J., Barbuch, R., & Bard, M. (2004) · Medical Mycology · doi:10.1080/13693780410001712016 · Cited by 26
Cited by
Fluconazole resistance in Candida species: a current perspective
Berkow, E., & Lockhart, S. (2017) · Infection and Drug Resistance · doi:10.2147/idr.s118892 · Cited by 542
Fitness Trade-offs Restrict the Evolution of Resistance to Amphotericin B
Vincent, B. M., Lancaster, A. K., Scherz-Shouval, R., Whitesell, L., & Lindquist, S. (2013) · PLoS Biology · doi:10.1371/journal.pbio.1001692 · Cited by 322
“The erg3 mutant demonstrated reduced virulence as previously reported [41–43], but still killed all”
BackgroundStress, drugs, and evolution: the role of cellular signaling in fungal drug resistance.
Cowen, L. E., & Steinbach, W. J. (2008) · Eukaryotic Cell · doi:10.1128/ec.00041-08 · Cited by 285
Identification and Characterization of Four Azole-Resistant erg3 Mutants of Candida albicans
Martel, C. M., Parker, J. E., Bader, O., Weig, M., Gross, U., Warrilow, A. G. S., Rolley, N., Kelly, D. E., & Kelly, S. L. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00348-10 · Cited by 168
“Clearly, just as no one resistance mechanism can explain azole resistance in C. albicans (6, 26, 28, 37), no mechanism (e.g., ERG3 mutation) should be disregarded.”
InfluentialMartel, C. M., Parker, J. E., Bader, O., Weig, M., Gross, U., Warrilow, A. G. S., Kelly, D. E., & Kelly, S. L. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00303-10 · Cited by 165
“albicans erg3 mutants are reportedly impaired in the ability to form filaments (3, 19), possibly because they lack the ergosterol-rich rafts associated with the leading edge of developing hyphae (17); this does not appear to be true of erg5 mutants.”
Background
Metadata
- Authors
- Miyazaki, T., Miyazaki, Y., Izumikawa, K., Kakeya, H., Miyakoshi, S., Bennett, J. E., & Kohno, S.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2006-02
- Volume
- 50
- Issue
- 2
- Pages
- 580-586
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2128344628
- Cited by
- 49
- References
- 13
- FWCI
- 1.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.